# Rapport Therapeutics Inc. (RAPP) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $25.44, market value $1.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Rapport Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.9×**. The shares trade at 2.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -6.6%** (5-yr avg -12.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -23.0%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 24.3%**. Earnings per share rose 24.3%.

## Financial health
- **Current ratio: 26.17** (quick 26.17). Current assets cover the next year's liabilities 26.17 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Rapport Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (14 analysts). 14 analysts cover Rapport Therapeutics Inc.; the consensus is strong_buy, with an average price target of $68.29 (+168% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -5.6%** (YTD -16.2%, 3-mo -39.7%). The shares are down 5.6% over twelve months including dividends.
- **From 52-week high: -51.9%** (15.3% above the low). Trading 52% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 39**. An RSI of 39 is neutral.
- **Beta (1 yr): 1.15** (volatility 62%). Beta of 1.15 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RAPP · Page: https://foliofundamentals.com/stocks/rapp

Not investment advice.